Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.
MDSCs
immunosuppression
immunotherapy
prostate cancer
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
22 12 2021
22 12 2021
Historique:
received:
17
11
2021
revised:
13
12
2021
accepted:
16
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
4
3
2022
Statut:
epublish
Résumé
Several lines of research are being investigated to better understand mechanisms implicated in response or resistance to immune checkpoint blockade in prostate cancer (PCa). Myeloid-derived suppressor cells (MDSCs) have emerged as a major mediator of immunosuppression in the tumor microenvironment that promotes progression of various tumor types. The main mechanisms underlying MDSC-induced immunosuppression are currently being explored and strategies to enhance anti-tumor immune response via MDSC targeting are being tested. However, the role of MDSCs in PCa remains elusive. In this review, we aim to summarize and present the state-of-the-art knowledge on current methodologies to phenotypically and metabolically characterize MDSCs in PCa. We describe how these characteristics may be linked with MDSC function and may influence the clinical outcomes of patients with PCa. Finally, we briefly discuss emerging strategies being employed to therapeutically target MDSCs and potentiate the long-overdue improvement in the efficacy of immunotherapy in patients with PCa.
Identifiants
pubmed: 35011582
pii: cells11010020
doi: 10.3390/cells11010020
pmc: PMC8750906
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
J Immunother Cancer. 2014 Sep 16;2:31
pubmed: 26196012
Front Oncol. 2015 Jan 12;4:375
pubmed: 25629002
Lancet Oncol. 2014 Jun;15(7):700-12
pubmed: 24831977
Cell Rep. 2015 Oct 13;13(2):412-24
pubmed: 26411680
Nature. 2018 Jul;559(7714):363-369
pubmed: 29950727
Front Immunol. 2014 Feb 24;5:69
pubmed: 24605112
Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103
pubmed: 9223321
Immunity. 2020 Apr 14;52(4):668-682.e7
pubmed: 32294407
Eur Urol. 2016 Mar;69(3):400-4
pubmed: 26144873
Nat Rev Drug Discov. 2007 Aug;6(8):662-80
pubmed: 17667957
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Cancer Res. 2018 Jun 15;78(12):3220-3232
pubmed: 29674477
Proc Natl Acad Sci U S A. 1978 Oct;75(10):5142-4
pubmed: 283421
Cancer Discov. 2013 Aug;3(8):849-61
pubmed: 23811619
Am J Pathol. 2007 Sep;171(3):928-37
pubmed: 17690184
J Immunother Cancer. 2018 Sep 18;6(1):91
pubmed: 30227893
Cancer Immunol Immunother. 2014 Nov;63(11):1177-87
pubmed: 25085000
Cancer Immunol Immunother. 2016 Feb;65(2):151-60
pubmed: 26728480
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Contemp Oncol (Pozn). 2018 Mar;22(1A):7-13
pubmed: 29628788
Prostate. 2010 Mar 1;70(4):443-55
pubmed: 19902470
Proc Natl Acad Sci U S A. 2017 Sep 26;114(39):10455-10460
pubmed: 28900008
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):28960-28970
pubmed: 33127761
Int Immunopharmacol. 2011 Jul;11(7):802-7
pubmed: 21237299
Gene. 2007 Jul 1;396(1):203-13
pubmed: 17499941
Oncoimmunology. 2016 Jun 27;5(7):e1196312
pubmed: 27622051
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Front Immunol. 2019 Mar 18;10:475
pubmed: 30936876
Hum Immunol. 2010 Jul;71(7):659-65
pubmed: 20438786
Cancer Res. 2017 Jun 1;77(11):2857-2868
pubmed: 28416485
Cancer Discov. 2016 Jan;6(1):80-95
pubmed: 26701088
Mol Cancer Res. 2017 Sep;15(9):1138-1152
pubmed: 28512253
J Immunotoxicol. 2012 Jul-Sep;9(3):275-81
pubmed: 22449053
J Immunol Methods. 2012 Jul 31;381(1-2):14-22
pubmed: 22522114
Proc Natl Acad Sci U S A. 2018 Jun 5;115(23):5839-5848
pubmed: 29802228
Cancer Chemother Pharmacol. 2016 Mar;77(3):549-58
pubmed: 26811179
J Leukoc Biol. 2017 Aug;102(2):423-436
pubmed: 28533357
Cell Immunol. 2021 May;363:104312
pubmed: 33652258
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
EMBO J. 2011 May 20;30(13):2719-33
pubmed: 21602788
Sci Rep. 2017 Nov 13;7(1):15424
pubmed: 29133913
EBioMedicine. 2019 Sep;47:235-246
pubmed: 31462392
Nat Med. 2010 Feb;16(2):219-23
pubmed: 20081861
Front Immunol. 2019 Apr 18;10:771
pubmed: 31057536
J Immunol. 2015 Dec 1;195(11):5237-50
pubmed: 26491198
J Exp Med. 2011 Sep 26;208(10):1949-62
pubmed: 21930770
JAKSTAT. 2013 Jan 1;2(1):e23010
pubmed: 24058791
Gynecol Oncol. 2017 Sep;146(3):484-490
pubmed: 28698009
Oncotarget. 2014 Jan 30;5(2):473-80
pubmed: 24457622
Pol J Pathol. 2020;71(1):46-54
pubmed: 32429654
Front Immunol. 2020 Jan 22;10:3070
pubmed: 32038621
Cancer Res. 2019 Oct 1;79(19):5034-5047
pubmed: 31409640
Cell Immunol. 2011;269(2):128-34
pubmed: 21477798
Curr Opin Urol. 2016 Nov;26(6):501-7
pubmed: 27471994
Cancer Immunol Res. 2015 Nov;3(11):1236-47
pubmed: 26025381
Oncologist. 2021 Dec;26(12):e2136-e2142
pubmed: 34427023
Front Immunol. 2020 Oct 02;11:02168
pubmed: 33123122
Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10094-10099
pubmed: 30232256
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
J Exp Med. 2010 Oct 25;207(11):2439-53
pubmed: 20876310
Lancet Oncol. 2007 Oct;8(10):912-20
pubmed: 17881290
Front Oncol. 2014 Dec 12;4:351
pubmed: 25566495
Cancers (Basel). 2017 Jan 27;9(2):
pubmed: 28134800
Int J Clin Exp Med. 2014 Oct 15;7(10):3181-92
pubmed: 25419348
J Thorac Oncol. 2016 Aug;11(8):1263-1272
pubmed: 27178984
J Biol Chem. 2002 Jun 14;277(24):21123-9
pubmed: 11950832
J Immunol. 1984 Jan;132(1):101-10
pubmed: 6228575
Nat Med. 2014 Jun;20(6):676-81
pubmed: 24859530
Nature. 2011 Feb 10;470(7333):269-73
pubmed: 21289624
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Cancer Res. 2014 Nov 1;74(21):6022-35
pubmed: 25209187
Nature. 2017 Mar 30;543(7647):728-732
pubmed: 28321130
Cancer Metastasis Rev. 2010 Dec;29(4):709-22
pubmed: 20839032
Vaccines (Basel). 2015 Sep 10;3(3):703-29
pubmed: 26378585
Oncotarget. 2016 Aug 16;7(33):52810-52817
pubmed: 27429197
Prostate. 2019 Oct;79(14):1611-1621
pubmed: 31348843
Cancer Res. 2010 Apr 15;70(8):3052-61
pubmed: 20388795
J Leukoc Biol. 2012 Jan;91(1):167-81
pubmed: 21954284
Cancer Res. 2007 Nov 15;67(22):11021-8
pubmed: 18006848
J Clin Oncol. 2017 Jan;35(1):40-47
pubmed: 28034081
Cancer Immunol Immunother. 2016 Mar;65(3):273-82
pubmed: 26786874
Oncoimmunology. 2015 Jan 07;4(3):e989764
pubmed: 25949902
Cancer Res. 2005 Dec 15;65(24):11565-71
pubmed: 16357166
Eur J Immunol. 2013 Nov;43(11):2943-55
pubmed: 23897117
Cell Immunol. 2004 Nov-Dec;232(1-2):21-31
pubmed: 15922712
J Clin Invest. 2019 Dec 2;129(12):5537-5552
pubmed: 31566578
Cancer Cell. 2003 Sep;4(3):209-21
pubmed: 14522255
J Invest Dermatol. 2013 Jun;133(6):1610-9
pubmed: 23223128
Cancer Immunol Immunother. 2014 Feb;63(2):175-83
pubmed: 24292263
Cell Immunol. 1979 Mar 15;43(2):372-81
pubmed: 476835
Cancer Sci. 2017 Dec;108(12):2326-2332
pubmed: 28898532
Cancer Immunol Res. 2020 Sep;8(9):1215-1227
pubmed: 32661092
Blood. 2011 Nov 17;118(20):5498-505
pubmed: 21972293
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2611-6
pubmed: 16477023
Front Immunol. 2019 Jun 19;10:1399
pubmed: 31275326
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Cancer Res. 2018 Oct 1;78(19):5644-5655
pubmed: 30139814
J Exp Med. 2005 Oct 3;202(7):931-9
pubmed: 16186186
Biochem Biophys Res Commun. 2011 Jul 1;410(2):195-200
pubmed: 21627959
Cell Rep. 2021 Oct 26;37(4):109883
pubmed: 34706232
Mol Cell Biol. 2014 Jun;34(11):2017-28
pubmed: 24662052
Int J Mol Sci. 2020 Mar 27;21(7):
pubmed: 32230980
Biology (Basel). 2020 Dec 01;9(12):
pubmed: 33271839
J Bone Miner Res. 2005 Feb;20(2):318-29
pubmed: 15647826
J Pathol Clin Res. 2020 Jul;6(3):171-177
pubmed: 32149481
Cancer Immunol Immunother. 2017 Aug;66(8):989-996
pubmed: 28224211
Cancer Res. 2015 Mar 15;75(6):950-62
pubmed: 25736687
Int Immunopharmacol. 2018 Oct;63:282-291
pubmed: 30121453
Clin Cancer Res. 2015 Aug 15;21(16):3771-82
pubmed: 25967142
Cancer Immunol Res. 2014 May;2(5):399-403
pubmed: 24795352
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Cancer J. 2013 Jan-Feb;19(1):50-8
pubmed: 23337757
J Immunother Cancer. 2017 Jan 17;5:5
pubmed: 28105371
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
Oncotarget. 2015 Jul 10;6(19):17302-13
pubmed: 26046794
Mol Cancer. 2013 Dec 09;12(1):154
pubmed: 24321240
PLoS One. 2012;7(11):e48871
pubmed: 23173040
Drug Des Devel Ther. 2015 Sep 07;9:5115-22
pubmed: 26379424
Clin Exp Metastasis. 2015 Feb;32(2):111-24
pubmed: 25617965
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938
Int J Urol. 2013 Oct;20(10):971-8
pubmed: 23421558
Front Immunol. 2020 May 15;11:938
pubmed: 32499785